Portland Trocars
510(k) K962193
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK962193 | Date28 Aug 1996 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- GCJ
- Device Class
- Class II
- Regulation
- 21 CFR Part 876.1500
- Advisory Committee
- Gastroenterology, Urology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
Portland Trocars are a laparoscope device classified under the product code GCJ for general and plastic surgery. They are substantially equivalent to a legally marketed device as determined by FDA 510(k) clearance.
The device was cleared by the FDA on August 28, 1996, under traditional 510(k) review, with submission received on June 7, 1996. It is classified as Class II with special controls and was reviewed by the Gastroenterology and Urology advisory committee.
Other devices from Surgical Innovations Plc
Questions
AI-generated answers, 1 Oct 2026
What is the Portland Trocars device used for?
The Portland Trocars are a laparoscope device intended for use in general and plastic surgery procedures, as indicated by their classification under product code GCJ.
When was the Portland Trocars device cleared by the FDA?
The Portland Trocars device received FDA 510(k) clearance on August 28, 1996, following a traditional review process with submission received on June 7, 1996.
What regulatory pathway was used for the Portland Trocars device?
The Portland Trocars device was cleared through the FDA's traditional 510(k) pathway, demonstrating substantial equivalence to a legally marketed predicate device.
Which advisory committee reviewed the Portland Trocars device?
The Portland Trocars device was reviewed by the Gastroenterology and Urology advisory committee during its FDA 510(k) submission process.